ALPINE IMMUNE SCIENCES, INC. — Net Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/37bd85ea-8b5a-49bd-89a2-0a4a80350eb0/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-32.2M | 2023-01-01 – 2023-12-31 | evidence 0001626199-24-000048 |
| FY 2022 | $-57.8M | 2022-01-01 – 2022-12-31 | evidence 0001626199-23-000037 |
| FY 2021 | $-50.3M | 2021-01-01 – 2021-12-31 | evidence 0001626199-22-000032 |
| FY 2020 | $-27.9M | 2020-01-01 – 2020-12-31 | evidence 0001626199-21-000038 |
| FY 2019 | $-41.9M | 2019-01-01 – 2019-12-31 | evidence 0001626199-20-000009 |
| FY 2018 | $-36.5M | 2018-01-01 – 2018-12-31 | evidence 0001626199-19-000010 |
| FY 2017 | $-7.8M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-006916 |
| FY 2016 | $-1.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-18-006916 |
| FY 2015 | $-369.0k | 2015-01-01 – 2015-12-31 | evidence 0001564590-18-006916 |
| FY 2014 | $-14.7M | 2014-01-01 – 2014-12-31 | evidence 0001558370-16-003896 |
| FY 2013 | $-16.2M | 2013-01-01 – 2013-12-31 | evidence 0001558370-16-003896 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ALPINE IMMUNE SCIENCES, INC. — all facts · Revenue · Operating Income